Загрузка...
Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.
Сохранить в:
| Опубликовано в: : | Clin Case Rep |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077276/ https://ncbi.nlm.nih.gov/pubmed/33936630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3927 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|